About 26S proteasome non-ATPase regulatory subunit 4
26S proteasome non-ATPase regulatory subunit 4 (PSMD4) is a protein
from Homo sapiens identified by UniProt accession
P55036, 377 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | 26S proteasome non-ATPase regulatory subunit 4 |
| UniProt accession | P55036 |
| Gene | PSMD4 |
| Organism | Homo sapiens |
| Length | 377 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (71)
Diseases linked to this target (Open Targets).
- HIV infection · score 0.46
- glioblastoma multiforme · score 0.30
- breast adenocarcinoma · score 0.30
- low grade glioma · score 0.29
- endometrial cancer · score 0.29
- lung adenocarcinoma · score 0.29
- esophageal cancer · score 0.28
- urinary bladder cancer · score 0.28
- squamous cell lung carcinoma · score 0.28
- head and neck squamous cell carcinoma · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P55036-F1 | alphafold | PREDICTED | 72.05 | — |
Amino-acid sequence (377 residues)
MVLESTMVCV DNSEYMRNGD FLPTRLQAQQ DAVNIVCHSK TRSNPENNVG LITLANDCEV LTTLTPDTGR ILSKLHTVQP KGKITFCTGI RVAHLALKHR QGKNHKMRII AFVGSPVEDN EKDLVKLAKR LKKEKVNVDI INFGEEEVNT EKLTAFVNTL NGKDGTGSHL VTVPPGPSLA DALISSPILA GEGGAMLGLG ASDFEFGVDP SADPELALAL RVSMEEQRQR QEEEARRAAA ASAAEAGIAT TGTEDSDDAL LKMTISQQEF GRTGLPDLSS MTEEEQIAYA MQMSLQGAEF GQAESADIDA SSAMDTSEPA KEEDDYDVMQ DPEFLQSVLE NLPGVDPNNE AIRNAMGSLA SQATKDGKKD KKEEDKK
Explore 26S proteasome non-ATPase regulatory subunit 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets